Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net Elfabrio Coverage & Prior Auth Update |…
    Ask Trek AI about this page
    ModifiedHealth NetPolicy CP PHAR.512

    Pegunigalsidase Alfa (Elfabrio) — Coverage Criteria

    Customize your policy alerts

    Sign up for Health Net Policy CP PHAR.512 alerts

    Get alerted when Policy CP PHAR.512 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for Elfabrio (pegunigalsidase alfa-iwxj) for treatment of adults with confirmed Fabry disease for Health Net lines of business including Commercial, HIM, and Medicaid.

    Policy Summary
    PayerHealth Net
    PolicyPegunigalsidase Alfa (Elfabrio) — Coverage Criteria
    Policy CodePolicy CP PHAR.512
    Change TypeCoding addition and criteria updates
    Effective DateMay 23, 2024
    Last ReviewMay 25, 2024
    Next Review DateMay 25, 2025
    Key ActionSubmit prior authorization with documentation of confirmed Fabry disease, specialist prescriber, current weight (kg), and ensure Elfabrio is not used concurrently with Fabrazyme or Galafold.
    SourceLink
    POLICY UPDATE CHANGES

    Added HCPCS code J2508 to coding.

    Added concomitant use exclusion to the Continued Therapy section to mirror the Initial Approval Criteria and added requirement for documentation of member's weight for dose calculation.

    References reviewed and updated during annual reviews (3Q 2024 and 2Q 2025) with no significant clinical changes otherwise.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    AdultsFDA-approved patient population
    1 mg/kgMaximum dosing
    6 moInitial approval duration
    12 moContinued approval duration
    J2508HCPCS code added
    Concomitant useNew exclusion

    Coverage Criteria

    inv-01: Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Initial Approval: 1) Diagnosis of Fabry disease confirmed by enzyme assay demonstrating alpha-galactosidase deficiency OR DNA testing; 2) Prescribed by or in consultation with a specialist (clinical geneticist, cardiologist, nephrologist, neurologist, lysosomal disease specialist, or Fabry disease specialist); 3) Patient is >= 18 years of age; 4) Documentation of current weight (kg); 5) Elfabrio is not prescribed concurrently with Fabrazyme or Galafold; 6) Dose does not exceed 1 mg/kg every 2 weeks.

    Approval duration: 6 months

    inv-02: Continuation Therapy — Covered for continuation when ALL of the following are met

    Covered for continuation when ALL of the following are met:

    Continuation: 1) Member is currently receiving Elfabrio via the health plan benefit or has previously met initial approval criteria; 2) Member is responding positively as evidenced by improvement in the individual's Fabry disease manifestation profile (examples in Appendix D); 3) Elfabrio is not prescribed concurrently with Fabrazyme or Galafold; 4) Documentation of current weight (kg); 5) If request is for a dose change, the new dose does not exceed 1 mg/kg every 2 weeks.

    Approval duration: 12 months

    inv-03: Continued Therapy (updated) — Continued Therapy criteria including updates

    Continued Therapy (updated)

    Continued Therapy requirements: Member must meet existing continued therapy criteria AND must not be using excluded concomitant therapies; documentation of current weight (kg) for dose calculation is required.

    Concomitant use exclusion was added to mirror the Initial Approval Criteria.

    Coverage does not authorize use of Elfabrio (pegunigalsidase alfa) for non‑FDA approved indications that are not specifically addressed in this policy. Such off‑label requests must be supported by sufficient documentation of efficacy and safety in accordance with the referenced off‑label use policies (CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid) or other evidence of coverage documents.

    For Continued Therapy, coverage excludes concomitant use of therapies that are specified in the Initial Approval Criteria. Continued approval requires documentation that the member is not receiving any excluded concomitant therapies; this exclusion was added to the Continued Therapy section to mirror the Initial Approval Criteria and was recorded during the 2Q 2025 update.

    Concurrent prescription of Elfabrio with either Fabrazyme or Galafold is explicitly disallowed. Requests where Elfabrio is prescribed simultaneously with Fabrazyme or Galafold are considered not medically necessary and are excluded from coverage.

    Coding

    HCPCS CodesHCPCSCovered
    J2508Injection, pegunigalsidase alfa-iwxj, 1 mg
    Covered HCPCS CodesHCPCSCovered
    J2508Pegunigalsidase alfa (HCPCS code) - added
    inv-09: Maximum dose — 1 mg/kg every 2 weeks
    Maximum dose1 mg/kg every 2 weeks

    Provider Actions and Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for initial therapy. Requests must include documentation confirming the diagnosis of Fabry disease and that the prescriber is a specialist (clinical geneticist, cardiologist, nephrologist, neurologist, lysosomal disease specialist, or Fabry disease specialist). Requests that lack required documentation (diagnosis confirmation, specialist prescriber, or member weight in kg) may be denied.

    • Prior authorization required for initial therapy with documentation of confirmed Fabry disease
    • Prescriber must be a specialist or consult with a listed specialist
    • Incomplete requests (missing diagnosis confirmation, specialist prescriber, or weight) may be denied
    Denial Risk

    Non‑FDA Indications

    Off‑label (non‑FDA) indications that are not addressed in this policy may be denied unless there is sufficient documentation of efficacy and safety per the applicable off‑label use policy for the line of business. Refer to the commercial, health insurance marketplace, or Medicaid off‑label policies as applicable.

    Background

    Fabry disease is an X‑linked lysosomal storage disorder caused by deficiency of the enzyme alpha‑galactosidase A, leading to accumulation of glycosphingolipids in multiple organ systems. Clinical manifestations can include peripheral neuropathic pain, angiokeratomas, hypohidrosis or anhidrosis, gastrointestinal symptoms, renal impairment progressing to proteinuria and chronic kidney disease, and cardiac involvement such as left ventricular hypertrophy and arrhythmia. Diagnosis is established by decreased enzyme activity on assay or by DNA testing, and management may include enzyme replacement therapy such as pegunigalsidase alfa (Elfabrio) for adults with confirmed disease.

    Definitions

    inv-21: Fabry disease manifestations — clinical signs and common manifestations
    Peripheral signsExtremity pain, hypohidrosis or anhidrosis, and angiokeratomas
    Gastrointestinal manifestationsDiarrhea, abdominal pain, nausea, vomiting, and flank pain
    Neurologic and sensory symptomsNeuropathic pain, heat/cold intolerance, vertigo, and diplopia
    Renal and systemic involvementRenal dysfunction or changes in renal function
    Other common featuresFatigue and cornea verticillata
    inv-22: Pegunigalsidase alfa (Elfabrio) — drug definition and formulation
    Generic description

    Initial Therapy Criteria

    inv-23: Initial Therapy — Initial coverage criteria (grouped block)

    Covered when ALL of the following are met:

    Initial Therapy: Confirmed Fabry disease by enzyme assay demonstrating alpha-galactosidase deficiency OR DNA testing; prescribed by or in consultation with a listed specialist; patient is >= 18 years of age; documentation of current weight (kg); Elfabrio is not prescribed concurrently with Fabrazyme or Galafold; dose does not exceed 1 mg/kg every 2 weeks.

    Approval duration: 6 months

    inv-24: Initial Therapy — Initial Approval Criteria referenced; concomitant use exclusion exists in Initial Approval Criteria

    Initial Approval Criteria referenced; concomitant use exclusion exists in Initial Approval Criteria.

    Initial Approval (reference): Refer to the Initial Approval Criteria for full details; a concomitant use exclusion (Elfabrio not to be used concurrently with Fabrazyme or Galafold) applies as documented in the Initial Approval Criteria.

    Details of initial criteria are in the Initial Approval Criteria section.

    Continuation / Continued Therapy Criteria

    inv-25: Continuation — Criteria for continued coverage

    Criteria for continued coverage

    Continuation: 1) Member currently receiving Elfabrio via the health plan benefit or has previously met initial approval criteria; 2) Positive clinical response demonstrated by improvement in Fabry disease manifestations (see Appendix D for examples); 3) No concurrent prescription of Fabrazyme or Galafold; 4) Documentation of current weight (kg); 5) If dose change requested, new dose does not exceed 1 mg/kg every 2 weeks.

    Approval duration: 12 months

    inv-26: Continuation Therapy — Continuation therapy updated to include exclusions and weight documentation

    Continuation therapy updated to include exclusions and weight documentation

    Continuation requirements (updated): Continuation of pegunigalsidase alfa requires meeting prior continuation criteria, absence of excluded concomitant therapies (per the Initial Approval Criteria), and documentation of the member's current weight (kg) for dose calculation; dose must not exceed 1 mg/kg every 2 weeks.

    Added during 2Q 2025 annual review.

    Step Therapy

    StepRequirement / InstructionReference
    Refer to formulary/non-formulary or off-label policiesWhen the requested use is not listed in this policy or has recently changed (e.g., new indication, age expansion, or dosing not reflected here), refer to the applicable formulary, non‑formulary, or off‑label use policy for the member's line of business.CP.CPA.190, HIM.PA.33 or CP.PMN.255 for formulary/no coverage; CP.CPA.09, HIM.PA.154 or CP.PMN.53 for off‑label use

    Quantity Limits

    inv-28: Pegunigalsidase alfa (Elfabrio) — quantity limit / dosing reference 1 mg/kg
    Quantity/dosing reference1 mg/kg per dose, administered every 2 weeks
    Unit basisDose calculated using documented current member weight in kilograms
    Limit contextMaximum dose not to exceed 1 mg/kg every 2 weeks per policy dosing guidance

    Revision History

    2024-05-13annual_review

    3Q 2024 annual review — references reviewed and updated (no significant clinical changes).

    2024-08-23coding_update

    HCPCS code J2508 (Injection, pegunigalsidase alfa-iwxj, 1 mg) was added to the policy coding.

    2025-03-10annual_review

    2Q 2025 annual review — added concomitant use exclusion to the Continued Therapy section and added requirement for documentation of member weight for dose calculation.

    Policy Summary
    PayerHealth Net
    PolicyPegunigalsidase Alfa (Elfabrio) — Coverage Criteria
    Policy CodePolicy CP PHAR.512
    Change TypeCoding addition and criteria updates
    Effective DateMay 23, 2024
    Last ReviewMay 25, 2024
    Next Review DateMay 25, 2025
    Key ActionSubmit prior authorization with documentation of confirmed Fabry disease, specialist prescriber, current weight (kg), and ensure Elfabrio is not used concurrently with Fabrazyme or Galafold.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and RequirementsBackgroundDefinitionsInitial Therapy CriteriaContinuation / Continued Therapy CriteriaStep TherapyQuantity LimitsRevision History
    • Non‑FDA indication requests require evidence per off‑label use policies: CP.CPA.09 (commercial), HIM.PA.154 (marketplace), CP.PMN.53 (Medicaid)
    • If the use is a recent label change not yet reflected here, follow the relevant line‑of‑business formulary/coverage guidance
    Denial Risk

    Documentation and Concomitant Use

    Providers must document absence of excluded concomitant therapies and provide member weight for dose calculation. Failure to document weight or the presence/absence of excluded concomitant use (for example, concurrent Fabrazyme or Galafold) may result in denial.

    • Elfabrio (pegunigalsidase alfa) is not to be prescribed concurrently with Fabrazyme or Galafold; providers must document that these therapies are not being used concomitantly
    • Documentation of the member's current weight (in kg) is required for dose calculation and must be submitted
    Documentation Required

    Required Clinical Documentation

    Submit supporting clinical documentation with the prior authorization request. Acceptable documentation includes office chart notes, laboratory results (e.g., enzyme assay or DNA testing confirming Fabry disease), and any other clinical information that demonstrates the member meets approval criteria.

    • Office notes, lab results (enzyme assay demonstrating alpha‑galactosidase deficiency or DNA testing), and specialist consultation notes as applicable
    • Documentation must support age, diagnosis confirmation, current weight (kg), dosing, and absence of excluded concomitant therapies
    Note

    Formulary / Off‑Label Referral

    Refer to formulary, non‑formulary, and off‑label policies when the requested use is not covered under this policy. For formulary and PDL items use the appropriate no coverage or non‑formulary policies for the line of business.

    • Formulary/no coverage policies: CP.CPA.190 (commercial), HIM.PA.103 or HIM.PA.33 (marketplace), CP.PMN.16 or CP.PMN.255 (Medicaid) as applicable
    • Non‑formulary or off‑label escalations should follow the referenced line‑of‑business policies
    Billing Rule

    Prior Authorization and Coding

    Added prior‑authorization and coding note: prior authorization is required for pegunigalsidase alfa. HCPCS code J2508 applies for billing.

    • HCPCS code J2508 added for pegunigalsidase alfa (check claim/billing guidance for date of applicability)
    Pegunigalsidase alfa (Elfabrio) is a PEGylated hydrolytic lysosomal neutral glycosphingolipid enzyme replacement therapy
    Proprietary nameElfabrio (pegunigalsidase alfa-iwxj)
    Route and classIntravenous enzyme replacement therapy for Fabry disease
    Pharmacologic modificationPEGylated formulation to modify pharmacokinetics
    2025-05-25p_and_t_approvalLatest

    P&T approval recorded for 2Q 2025 updates including the concomitant use exclusion and weight documentation requirement for Continued Therapy.